When the FDA approved Foundayo (orforglipron) on April 1, 2026, it didn't just add another GLP-1 to the menu. It introduced the first oral GLP-1 weight loss medication that can be taken at any time of day, with or without food and water. For patients who found injectable GLP-1s inconvenient or the Wegovy pill's strict fasting requirements burdensome, Foundayo represents a genuinely new option.
Within weeks of approval, telehealth platforms began racing to offer it. Here's what's available, how the pricing works, and what to know before you sign up.
What Makes Foundayo Different
Foundayo is a once-daily oral pill, but it's not just an oral version of an existing injectable. Orforglipron is a small-molecule compound — chemically distinct from the peptide-based GLP-1 medications like semaglutide and tirzepatide. This distinction matters because it's what allows Foundayo to be absorbed without the food, water, and timing restrictions that apply to oral semaglutide (the Wegovy pill).
The Wegovy pill requires patients to take it on an empty stomach with no more than 4 ounces of water, then avoid eating or drinking for at least 30 minutes. Foundayo has no such restrictions. You can take it at breakfast, with your morning coffee, or at bedtime — whatever fits your routine.
In terms of effectiveness, the clinical data shows Foundayo produces meaningful but somewhat more modest weight loss compared to injectable semaglutide or tirzepatide. In the ATTAIN-1 trial, patients with obesity achieved an average weight loss of about 12.4% at the highest dose (36 mg) over 72 weeks — roughly 27 pounds for a typical patient. By comparison, injectable semaglutide (Wegovy) trials showed approximately 15% weight loss, and tirzepatide (Zepbound) showed approximately 20%.
That's a real difference, but it's also a real result. A 12% body weight reduction is clinically significant and exceeds what older weight loss medications typically achieve.
Where Foundayo Is Available Through Telehealth
Foundayo became available through Eli Lilly's direct-to-consumer platform, LillyDirect, on April 6, 2026 — just five days after FDA approval. Since then, it has rolled out to retail pharmacies and telehealth providers nationwide.
LillyDirect
Eli Lilly's own platform connects patients with independent telehealth providers who can evaluate and prescribe Foundayo. The medication is then fulfilled through Lilly's partnered pharmacies and shipped directly to the patient. This represents Lilly's move to control more of the patient experience from prescription to delivery.
Established telehealth platforms
Multiple established telehealth weight loss platforms have added Foundayo to their offerings. FuturHealth announced in late April 2026 that its affiliated clinical providers can prescribe Foundayo to eligible members nationwide. Walgreens Weight Management, Lemonaid Health, GoodRx Care, and WeightWatchers Clinic have also begun offering Foundayo alongside their existing GLP-1 options.
Traditional healthcare channels
Foundayo is also available through traditional pathways — your primary care physician or specialist can prescribe it, and it can be filled at major retail pharmacies including CVS, Walgreens, and others. It's not telehealth-exclusive.
Pricing Through Telehealth
Foundayo's pricing structure through Eli Lilly's savings program (as of May 2026):
Starting doses (3 mg – 12 mg): $149 per month with Lilly's savings card for eligible self-pay patients. This covers the titration period, which typically lasts several months.
Maintenance doses (14.5 mg and 17.2 mg): $299 per month with the savings card. The savings card provides an automatic discount on these higher doses, but requires refilling within 45 days of your previous prescription to maintain eligibility.
Highest dose (36 mg): Also $299 per month with the savings card.
These prices are the medication cost only. If you're using a telehealth platform (other than LillyDirect), there may be additional consultation or platform fees on top of the medication cost.
Patients covered by government insurance programs like Medicare and Medicaid are not eligible for the manufacturer savings card, though Medicare beneficiaries may be eligible for the GLP-1 Bridge program beginning July 2026, which could provide coverage at approximately $50/month.
Foundayo vs. Other Oral GLP-1 Options
Foundayo is not the only oral GLP-1 available. The Wegovy pill (oral semaglutide 25 mg) received FDA approval for weight management in December 2025. Here's how they compare:
Convenience: Foundayo wins decisively. No food or water restrictions, any time of day. The Wegovy pill must be taken on an empty stomach with limited water, followed by a 30-minute fast.
Weight loss: The Wegovy pill has shown approximately 14–15% body weight reduction in trials — slightly higher than Foundayo's 12.4% at the highest dose. Both are clinically meaningful.
Pricing: Both start at $149/month with manufacturer savings programs. At maintenance doses, Foundayo is $299/month; the Wegovy pill ranges up to $299/month for higher doses as well. The pricing is comparable, though specific savings program terms differ.
Mechanism: Different. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist. Wegovy pill (semaglutide) is a peptide-based GLP-1 receptor agonist in oral form. Both activate the same receptor but through chemically different compounds.
Side effects: Both share the common GLP-1 class side effects — nausea, vomiting, diarrhea, constipation — which tend to be most pronounced during dose titration and improve over time. The side effect profiles in clinical trials were broadly comparable.
What Telehealth Platforms Should Be Telling You
A responsible telehealth platform offering Foundayo should be transparent about several things:
This is a brand-name, FDA-approved medication. There is no compounded version of orforglipron. Every Foundayo prescription you receive is the FDA-approved product manufactured by Eli Lilly. This is a straightforward advantage over the compounded GLP-1 market, where product quality can vary.
The savings card has conditions. Lilly's savings program can expire, change, or be terminated at the company's discretion. The current terms are valid through December 31, 2026. A responsible provider will explain what happens to your pricing if the savings program ends.
Weight loss results are more modest than injectable options. Foundayo's convenience comes with a trade-off in weight loss magnitude. A provider who presents Foundayo as equivalent to injectable semaglutide or tirzepatide in terms of weight loss results is not being accurate. Foundayo is a strong option for patients who prioritize oral convenience, but patients seeking maximum weight loss may be better served by injectable options.
The label includes a boxed warning. Like all GLP-1 receptor agonists, Foundayo carries a boxed warning for thyroid C-cell tumors. It should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A proper medical evaluation should screen for these contraindications.
How to Access Foundayo Through Telehealth
If you're interested in Foundayo, the process is straightforward:
Choose a platform. You can go through LillyDirect, a third-party telehealth platform that offers Foundayo, or ask your existing primary care provider for a prescription. LillyDirect has the advantage of tight integration with Lilly's savings program and fulfillment network, but it's not your only option.
Complete a medical evaluation. You'll need a clinical assessment confirming you meet the prescribing criteria (BMI ≥30 or BMI ≥27 with a weight-related comorbidity) and screening for contraindications.
Start titration. Foundayo follows a structured dose titration schedule over approximately 20 weeks, starting at 3 mg and increasing through 6 mg, 12 mg, and optionally 14.5 mg and 17.2 mg before reaching the maximum 36 mg dose. Your provider will guide the titration based on your tolerance and response.
Plan for ongoing care. GLP-1 treatment works best with ongoing clinical oversight, lifestyle modification, and periodic follow-up. Make sure whatever platform you choose provides this, rather than just an initial prescription.
The Bottom Line
Foundayo is a legitimately exciting addition to the GLP-1 landscape — the first oral GLP-1 weight loss medication with no food or water timing restrictions. Its availability through telehealth platforms, combined with Lilly's $149–$299/month savings program, makes it accessible to a wide range of patients. Just be sure you understand the realistic pricing at maintenance dose, the weight loss data relative to other options, and the clinical requirements for safe use.